An inflammatory protein called ASC was found in laboratory models to help accelerate the toxic spread of alpha-synuclein through the brain in Parkinson’s disease, implying that this protein may be a useful disease target, a new study suggests. “Importantly, … the ASC protein presents as a promising target,” the…
News
Results from a Phase 1 clinical trial testing the experimental vaccine UB-312 in people with Parkinson’s disease are expected this summer, according to the therapy’s developer Vaxxinity. “Vaxxinity remains on track to meet critical milestones in 2023,” Mei Mei Hu, the company’s CEO, said in a press…
Researchers at the University of Rochester Medical Center are hoping to use digital tools, including the smartphone app mPower, to collect more precise and comprehensive long-term data about Parkinson’s disease. The study, called AT-HOME PD2, is supported by a $4.9-million grant from the National Institutes of Neurological…
Parkinson’s disease patients in Japan reported a general worsening of their symptoms and less time spent out of the house during the COVID-19 pandemic in a recent survey study. As a result, caregivers reported an increased burden that was accompanied by more frustration and fatigue. “For future emergency control…
Many elderly people who do not have Parkinson’s disease nonetheless experience some Parkinson’s-like symptoms, especially slowness of movement, a new study from Sweden highlights. These symptoms, while reported to impact quality of life, typically are not enough to warrant a formal Parkinson’s diagnosis. Instead, they’re often referred to…
People with post-traumatic stress disorder (PTSD) were found to be at a higher risk of Parkinson’s disease or related neurodegenerative conditions, a small meta-analysis suggests. “The small number of studies to date provide preliminary evidence of an association between mid- to late-life onset PTSD and subsequent development of [Parkinson’s]…
A novel machine learning tool, called CRANK-MS, was able to identify, with high accuracy, people who would go on to develop Parkinson’s disease, based on an analysis of blood molecules. The algorithm identified several molecules that may serve as early biomarkers of Parkinson’s. These findings show the potential of…
Supernus Pharmaceuticals plans to resubmit its application seeking approval of SPN-830, its apomorphine infusion pump for people with Parkinson’s disease, to the U.S. Food and Drug Administration (FDA) by the end of this year. The decision comes after a meeting with the FDA last month at which…
The natural brain-produced steroid pregnenolone showed benefits in a rat model of Parkinson’s disease, where it was found to slow the development of levodopa-induced dyskinesia, or uncontrollable involuntary movements. Importantly, the treatment did not affect levodopa-induced motor improvements in the model. “Our data suggest that restoring…
Acorda Therapeutics has entered into an agreement with Chance Pharmaceuticals for Inbrija (levodopa inhalation powder), a medication used to treat symptoms during off episodes in Parkinson’s disease, to become available in China. Parkinson’s is a growing problem in China due to the country’s aging population; by…
Recent Posts
- When saying no feels like the hardest part of Parkinson’s caregiving
- Researchers ID compound that may slow Parkinson’s progression
- ‘If it ain’t broke, break it’: Lessons for Parkinson’s caregivers
- New campaign aims to boost early recognition of Parkinson’s symptoms
- New AI companion tool helps track Parkinson’s symptoms, guide care